Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio, Inc. (KRON) is a clinical-stage biopharmaceutical company pioneering small molecule therapeutics that target deregulated transcription in cancer and autoimmune disorders. This page provides investors and industry observers with essential updates on the company’s progress, including clinical trial milestones, financial disclosures, and strategic partnerships.
Access real-time announcements about KRON’s innovative pipeline candidates, including CDK9 and p300 KAT inhibitors designed to address high-need oncology indications. Our curated news collection offers insights into the company’s proprietary discovery engine and precision medicine approach while maintaining compliance with financial reporting standards.
Key updates cover earnings reports, research collaborations, regulatory developments, and scientific presentations. Bookmark this page for streamlined access to KRON’s latest advancements in transcription factor therapeutics and biopharmaceutical innovation.
Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Dr. Roger Dansey to its Board of Directors on April 24, 2023. Dr. Dansey, an expert in oncology drug development, currently serves as the president of research and development at Seagen Inc. His extensive experience includes senior leadership roles at Merck, Gilead Sciences, and Amgen. CEO Norbert Bischofberger welcomed Dr. Dansey, emphasizing his deep understanding of the clinical research landscape, which will significantly aid Kronos in advancing its product portfolio targeting dysregulated transcription. The company is pursuing two investigational compounds, KB-0742 for MYC-amplified tumors and lanraplenib for FLT3-mutated acute myeloid leukemia, highlighting its focus on innovative cancer therapies.
Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Katherine Vega Stultz to its Board of Directors, effective April 11, 2023, following the departure of Otello Stampacchia, Ph.D. on March 31, 2023. Stultz brings over 25 years of biopharmaceutical experience, currently serving as CEO of Ocelot Bio and previously holding significant roles at Graphite Bio and Celgene. CEO Norbert Bischofberger expressed confidence that Stultz's expertise in oncology drug development will enhance Kronos' clinical pipeline efforts. Kronos Bio focuses on developing therapies for challenging cancers, including investigational compounds like the CDK9 inhibitor KB-0742 and lanraplenib for acute myeloid leukemia.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
